William Kuziel Director, External Scientific Affairs Daiichi Sankyo William received his PhD in Immunology in 1988 from the University of Texas Southwestern Graduate School of Biomedical Sciences. In the External Scientific Affairs group within Daiichi Sankyo, he focuses on in licensing biologics and related technologies.
Pam Trail VP Regeneron Pharmaceuticals Pamela Trail is Vice President Oncology at Regeneron. Prior to this she served as the VP of Oncology at MedImmune and held positions at Seattle Genetics, Bayer, and Bristol-Myers Squibb. Dr. Trail has over 20 years of experience in developing antibody drug conjugates as cancer therapeutics. She received her PhD from the University of Connecticut.
Neil Bander Professor Weill/Cornell Medical College Neil Bander is the Bernard and Josephine Chaus Professor of Urologic Oncology at Weill/Cornell Medical College and Memorial Sloan-Kettering Cancer Center. Dr. Bander is a physician-scientist whose clinical and laboratory research efforts focus on the discovery and development of antibody-based imaging and therapeutic agents for urologic cancers. Read more...
Sanela Bilic Senior Fellow, Clinical Pharmacology Novartis
Paul Davis CEO Quanta BioDesign Paul’s vision for providing a full range of specifically designed single molecule reagents for therapeutic and diagnostic applications can be seen in the expanding range of products offered by Quanta. Paul has his Ph.D. in chemistry, and has almost 30 years of R&D experience. Before starting Quanta, he held key technical/management positions at Molecular Probes Life Technologies and Pierce Thermo Fisher.
Jonathan Drachman Senior VP Seattle Genetics Jonathan Drachman joined Seattle Genetics in November 2004. He oversees the company's research, preclinical and early clinical development activities. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School.
Trevor Hallam CSO Sutro Biopharma Dr. Hallam brings more than 25 years of experience in drug discovery and development to Sutro. Most recently, he was executive vice president of research & development and executive officer at Palatin Technologies where he was responsible for discovery and clinical development and led the development of several INDs for drug candidates in a variety of therapeutic areas. Read more...
Jagath Junutula Scientist Genentech Jagath Reddy Junutula joined Genentech, Inc. in 2001 and is currently a Group Leader in the Research and Early Development Division (gRED). He obtained his Ph.D. in 1997 from Indian Institute of Science, Bangalore, India. Jagath has extensive experience in protein engineering, molecular enzymology and the functional role of GTPases in the protein targeting and intracellular trafficking. Read more...
William Olson Principal Scientist Progenics Bill joined Progenics in 1994. He has also served as a Research Scientist at Johnson & Johnson, and as a Development Scientist at MicroGeneSys. He received his PhD from MIT.
Paul Parren Senior VP & Scientific Director Genmab Dr. Parren has been working in the field of recombinant antibodies for 25 years. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Dr. Parren serves in the position of Senior Vice President and Scientific Director and heads the Genmab Utrecht site.
George Pettit Regents Professor of Chemistry Arizona State University George R. Pettit, Ph.D. attended Washington State University where he completed (1952) the BS degree in Chemistry. He proceeded to Wayne State University and earned the MS degree in heterocyclic chemistry in 1954 and the Ph.D. in steroid chemistry in 1956. Both were under the direction of Professor Carl Djerassi, who discovered the first practical oral contraceptive. Dr. Pettit then finished a one-year postdoctoral in a pharmaceutical unit of Proctor & Gamble Co. Read more...
Mark Wright Site Lead, High Potency ADC Unit Piramal Healthcare Mark Wright is the Development Manger at Piramal Healthcare for Research and Development projects in the antibody drug conjugate field. He has been working with ADC projects at Piramal Healthcare for 6 years and has been working with protein - toxin conjugates for 9 years.
John Burt CEO Polytherics John joined PolyTherics in November 2010 and became CEO of the company in May 2011. He led the company through a successful financing round in 2011, completed the acquisition of Warwick Effect Polymers in January 2012 and is leading the transformation of the company into a successful technology commercialisation program with a growing presence in the ADC field. Read more...
Kinney Horn Associate Director, Business Development Genentech Kinney Horn is an Associate Director in Business Development at Genentech. Mr. Horn is involved in licensing transactions for novel therapeutics, technologies and intellectual property. Mr. Horn joined Genentech in 2003 in the R&D finance group. Read more...
Juhani Saarinen CEO Glykos Juhani Saarinen is the CEO of Glykos ltd, a Finland based biotech working with some of the world’s largest pharmaceutical companies on glycomics related projects. Mr. Saarinen is an inventor in over 25 patent families ranging from ADC technologies, cancer and cancer stem cells to engineering of therapeutic proteins and stem cell glycomics.
Dennis Benjamin Vice President, Experimental Therapeutics Seattle Genetics
John Lambert EVP & CSO ImmunoGen
Jay Harper Scientist II, Oncology Research MedImmune
Laurent Ducry Group Leader, Bioconjugates R&D Lonza
Pavel Strop Associate Research Fellow Pfizer
Henry Lowman CSO Cytomx Therapeutics
Damon Meyer Principal Scientist Seattle Genetics
David Jackson Principal Scientist & ADC Program Leader Igenica
Paul Davis Owner Quanta Biodesign
Dhaval Shah Senior Scientist Pfizer
Dimiter Dimitrov Head, Protein Interaction Group, Senior Investigator NCI
Florence Lhospice Director, Pharmaceutical Operations Innate Pharma
Melissa Schutten Scientist-Pathologist Genentech
Kevin Haehl Director, Global BD, Advanced Technologies Evonik
Tim Lowinger CSO Mersana Therapeutics
Ed Reilly Associate Director II, Cancer Therapeutic Abs, GPRD, Cancer Discovery AbbVie
Frank Koehn Research Fellow, Natural Products/World Wide Medicinal Chemistry Pfizer
Jan Pinkas Director ImmunoGen
Yilma Adem Formulation Scientist Genentech
Dave Colcher Deputy Director, Division of Radioimmunotherapy City of Hope
John Flygare Senior Scientist Genentech
Nitya Ray Senior VP, Manufacturing Progenics Pharmaceuticals
Kevin Pinney Professor of Chemistry, Department of Chemistry & Biochemistry Baylor University
Omar Kabbarah Scientist, Oncology Biomarker Development Genentech
Allan Ader Vice President & Principal Toxicologist SafeBridge Consultants Inc
Godfrey Amphlett Vice President, Process & Analytical Development ImmunoGen
Karyn O’Neil CSO Centyrex, Johnson & Johnson
April Xu Senior Principle Scientist & Group Leader Pfizer
Petter Veiby Global Head of Biotherapeutics, Oncology DDU Millennium
David Goldenberg Chairman & CSO Immunomedics
Greg Landes Biotechnology Consultant DNA Bridges
Maria Elena Guadagno Business Director BSP Pharmaceuticals
Steve Nail Senior Baxter Research Scientist Baxter Biopharma Solutions
Cynthia Wooge Global Strategic Marketing SAFC
Ellie Guardino Medical Director Genentech
Jiang He Associate Professor University of Virginia
Elizabeth Homans VP, Regulatory Strategic Services Genentech
Michele Dougherty Product Quality Reviewer, Division of Monoclonal Antibodies FDA
Matthew Hutchinson Senior Engineer Genentech
David Miao Founder & CSO Concortis Biosystems
Iwan Bertholjotti Head of ADC Program Management Lonza Visp
Conrad Roten Head of R&D for HPAPI/Cytotoxics Lonza Visp
John Atkinson Director, Toxicology Agensys
Alison Keene Head of Global Regulatory Affairs Lonza Pharma
Dan Pereira Senior Director, Discovery Research Agensys
James Garrison Head, Business Development & Commercial Strategy Progenics Pharmaceuticals